Encyclopedia of Pathology

Living Edition
| Editors: J.H.J.M. van Krieken

Hemosiderotic Fibrolipomatous Tumor

  • Bernadette Liegl-AtzwangerEmail author
Living reference work entry
DOI: https://doi.org/10.1007/978-3-319-28845-1_5397-1



Is a locally aggressive fibrolipomatous, hemosiderin-rich neoplasia

Clinical Features

  • Incidence

    Rare soft tissue neoplasm

  • Age

    Occur mainly in the fifth and sixth decade of life (Marshall-Taylor and Fanburg-Smith 2000; Browne and Fletcher 2006).

  • Sex

    Affects predominantly women (Marshall-Taylor and Fanburg-Smith 2000; Browne and Fletcher 2006).

  • Site

    Most commonly affected sites are the dorsum of the foot and the ankle region. Less frequently effected regions include the upper limbs, hands, and the head/neck region (Marshall-Taylor and Fanburg-Smith 2000; Browne and Fletcher 2006).

  • Treatment

    Complete surgical excision is the treatment of choice.

  • Outcome

    The local recurrence rate is 30–50% if initially incompletely excised. Complete excision is generally curative (Marshall-Taylor and Fanburg-Smith 2000; Browne and Fletcher 2006).


HFLT is an ill-defined yellowish-brown tumor with a tumor size ranging from 1 to 20 cm...

This is a preview of subscription content, log in to check access.

References and Further Reading

  1. Antonescu, C. R., Zhang, L., Nielsen, G. P., et al. (2011). Consistent t(1;10) with rearrangements of TGFBR3 and MGEA5 in both myxoinflammatory fibroblastic sarcoma and hemosiderotic fibrolipomatous tumor. Genes, Chromosomes and Cancer, 50, 757–764. PMID: 21717526.CrossRefGoogle Scholar
  2. Browne, T. J., & Fletcher, C. D. (2006). Haemosiderotic fibrolipomatous tumour (so-called haemosiderotic fibrohistiocytic lipomatous tumour): Analysis of 13 new cases in support of a distinct entity. Histopathology, 48, 453–461. PMID: 16487368.Google Scholar
  3. Elco, C. P., Mariño-Enríquez, A., Abraham, J. A., et al. (2010). Hybrid myxoinflammatory fibroblastic sarcoma/hemosiderotic fibrolipomatous tumor: Report of a case providing further evidence for a pathogenetic link. The American Journal of Surgical Pathology, 34, 1723–1727. PMID: 20871391.PubMedGoogle Scholar
  4. Hallor, K. H., Sciot, R., Staaf, J., et al. (2009). Two genetic pathways, t(1;10) and amplification of 3p11–12, in myxoinflammatory fibroblastic sarcoma, haemosiderotic fibrolipomatous tumour, and morphologically similar lesions. The Journal of Pathology, 217, 716–727. PMID: 19199331.CrossRefGoogle Scholar
  5. Marshall-Taylor, C., & Fanburg-Smith, J. C. (2000). Hemosiderotic fibrohistiocytic lipomatous lesion: Ten cases of a previously undescribed fatty lesion of the foot/ankle. Modern Pathology, 13, 1192–1199. PMID: 11106076.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Diagnostic and Research Institute of Pathology, Medical University of GrazGrazAustria